Teicoplanin

General	
• Class of the drug:	Glycopeptide antibiotics
• Synonym(s):	
• Common trade name(s) in Switzerland:	Targocid®
• Conversion factors:	Not applicable
Clinical pharmacology	
• Indications for TDM:	Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding:	90% (serum albumin)
• Elimination half-life:	70 -150 h pediatric: 58 h
• Volume of distribution:	1.1 l/kg
• Metabolism:	
- Main metabolic pathways:	No metabolites identified
- Active metabolite(s)?	None
- Inhibitor or inducer of the cytochrome P450 system?	No
- Other significant pharmacokinetic interactions:	None
• Elimination of parent drug:	Renal (80%)
• Typical therapeutic range:	Trough concentration: < 15 mg/l
• Potentially toxic concentration:	Not known
Pre-analytics	
• Time to steady-state since beginning of treatment or change of posology:	Not relevant
• Time for blood sampling:	Trough: within 30 minutes of next dose
• Type(s) of sample:	Serum or plasma
• Stability:	1 week at 4°C

Analytics	
• Position(s) in the analysis list/Method:	8628.01 Immunological
Remarks	• Elimination is strongly dependent on renal function • Avoid gel tubes if possible, unless having confirmed that no binding occurs
References	• Arzneimittel Kompendium der Schweiz 2005 • Thomson Micromedex® Healthcare series • Begg et al., Br J clin Pharm 39 (1995) 597 • Begg et al., Br J clin Pharm 7 (1999) 23 • Touw et al.,Ther Drug Monit 27 (2005) 10 • Schultz et al., Pharmazie 58 (2003) 447